20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia Platform
Rhea-AI Summary
20/20 BioLabs (Nasdaq: AIDX) announced that its OneTest™ for Cancer is now available through the Evexia Diagnostics platform, effective April 7, 2026. The collaboration gives OneTest broader visibility across Evexia’s network of ~40,000 functional and integrative medicine practitioners to support adoption and clinical access.
The partnership aims to simplify ordering and integration into clinical workflows while enabling practitioners to use OneTest’s biomarker quantification for baseline and longitudinal patient monitoring.
Positive
- Expanded access to ~40,000 Evexia practitioners
- Commercial distribution channel integration into clinical workflows
- Test capability includes biomarker identification and quantification for monitoring
Negative
- No financial terms or revenue projections disclosed for the Evexia distribution agreement
News Market Reaction – AIDX
In the Apr 7 session, AIDX declined 5.45%, reflecting a notable negative market reaction. Argus tracked a peak move of +15.5% during that session.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 31 | FY2025 earnings | Positive | +0.0% | Reported FY2025 growth, margin expansion, lower opex and improved net loss. |
| Mar 27 | Funding news | Positive | +4.0% | Maryland funds firefighter cancer screenings using OneTest MCED blood test. |
| Mar 24 | Licensing deal | Positive | -17.6% | Exclusive U.S. license to integrate CKD prediction into Longevity platform. |
| Mar 12 | Clinical technology | Positive | -8.5% | Highlighted protein biomarker advantages and validation data for MCED approach. |
| Feb 25 | Product launch | Positive | -28.8% | Launched OneTest for Longevity using IBM AI for chronic disease risk. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has often been positive but price reactions skew toward downside or flat moves, with only one of the last five items showing a positive alignment.
Over the last few months, AIDX reported FY2025 results with $2.0M revenue and narrowing losses, announced state-backed firefighter screenings, signed a CKD prediction license with ROKIT, and promoted advantages of its multi-cancer platform alongside a new OneTest for Longevity launch. Despite these bullish-sounding milestones, four of the last five releases saw flat or negative next-day reactions, suggesting a history of cautious market reception that frames today’s commercial distribution update.
Key Terms
multi-cancer early detection medical
biomarkers medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Joint Release Expands 20/20 BioLabs’ Testing Solutions Across Evexia’s Network of ~40,000 Functional and Integrative Medicine Practitioners
Marks a Commercial Expansion Milestone for OneTest for Cancer Across Evexia’s National Practitioner Network
WASHINGTON, Conn. and GAITHERSBURG, Md., April 07, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases today announced that its OneTest™ for Cancer is now available through the Evexia Diagnostics platform, a leading marketplace that enables functional and integrative medicine practitioners to easily discover, order and manage advanced diagnostic testing solutions.
Through this collaboration, 20/20 BioLabs’ testing solutions will gain broader visibility and accessibility across Evexia’s network of more than 40,000 functional and integrative medicine practitioners, helping support expanded adoption among providers seeking advanced tools to better assess patient health and inform care decisions.
“Making our testing solutions available through Evexia is an important commercial step for 20/20 BioLabs,” said Jonathan Cohen, Chief Executive Officer of 20/20 BioLabs. “Evexia has built a highly efficient platform that connects innovative diagnostics companies with a large network of engaged practitioners. We believe this relationship will help broaden awareness of our offerings and support continued growth as we work to bring more data-driven health insights to providers and patients.”
Ryan Obermeier, Chief Commercial Officer at Evexia Diagnostics, added, “We are excited to introduce OneTest™ for Cancer to our growing network of specialty laboratory partners. After a thorough evaluation of available multi-cancer early detection (MCED) options, we selected OneTest for its combination of affordability and strong sensitivity for earlier-stage cancers. What truly sets this test apart is its ability to identify specific biomarkers and quantify their levels. This enables clinicians and patients to establish a personalized baseline and monitor changes over time—making OneTest a powerful tool for proactive care and long-term health tracking.”
Evexia’s platform is designed to simplify the process of identifying and ordering laboratory tests, supplements, and other health products for practitioners operating in functional and integrative medicine. By joining the platform, 20/20 BioLabs is positioned to reach a large and relevant practitioner audience through a channel that is already integrated into clinical workflows.
The companies expect the collaboration to support greater exposure for 20/20 BioLabs’ offerings while providing Evexia practitioners with access to differentiated testing solutions designed to help inform earlier and more personalized care decisions.
About Evexia Diagnostics
Evexia Diagnostics stands out in the clinical laboratory services landscape, catering primarily to the Functional and Integrative Medicine communities. Founded in 2007, Evexia offers comprehensive, cutting-edge laboratory services at unbeatable prices. Its proprietary infrastructure is designed to meet the needs of both licensed and non-licensed-to-order clinicians, delivering fast, affordable, and reliable solutions to enhance client efficiency and profitability.
About 20/20 BioLabs
20/20 BioLabs, Inc. (Nasdaq: AIDX) develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The Company offers two families of lab tests under the OneTest brand. OneTest™ for Cancer is a multi-cancer early detection, or MCED, blood test, and OneTest for Longevity™, which measures inflammatory biomarkers, expected to launch in the first half of 2026. OneTest’s affordable, accurate, accessible tests can be conveniently utilized at home using new, upper arm capillary collection devices that avoid painful needles. Tests are run in its College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, MD. For more information, please visit 2020biolabs.com.
Forward-Looking Statements
Certain statements in this release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that it believes may affect its financial condition, results of operations, business strategy, and financial needs. Forward-looking statements can be identified by words such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project,” “continue,” or the negative of these terms or other comparable expressions. Actual results may differ materially from those expressed or implied by such forward-looking statements. A number of factors could cause actual results to differ materially from those contained in these forward-looking statements, including, but not limited to, the risks described in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), available on the SEC’s website at www.sec.gov, including the Company’s Annual Report on Form 10-K, filed with the SEC on March 31, 2026, as well as in our other reports filed or furnished from time to time with the SEC. The Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events, except as required by applicable law. Although the Company believes the expectations expressed in these forward-looking statements are reasonable, it cannot guarantee future results, and investors are cautioned that actual outcomes may differ materially from those anticipated.
Contacts
Evexia Diagnostics
Ryan Obermeier
+1 888-852-2723
email us here
20/20 BioLabs
Investor Relations
Chris Tyson
MZ Group
Direct: 949-491-8235
AIDX@mzgroup.us
